Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...
This transcript has been edited for clarity. Andrew N. Wilner, MD: Welcome to Medscape. I'm your host, Dr Andrew Wilner, reporting on the annual American Epilepsy Society meeting. With me today is my ...
Researchers have gained new insights into the cellular and molecular mechanisms of absence seizures and potential therapy options. Stimulation of certain cerebellar areas could help combat absence ...
“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...
“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...
SRF (SYNGAP1), RSRT (Rett), CACNA1A, STXBP1, Loulou (CDKL5), & KCNQ2 Cure (KCNQ2) collaborate to support Dr. Devinsky’s research for clinical trial readiness. Co-funded by multiple organizations, this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results